




# Changing the World: Advancing Innovation

2025 ANNUAL REPORT

# A History of Time: PCF's Extraordinary Legacy of Science



Dozens of PCF Young Investigators were honored at the 2012 Celebration of Science.



PCF funded Dr. Jim Allison's UC Berkeley work, which led to ipilimumab (Yervoy®), a first-in-class immunotherapy. Millions have benefitted.

Since 1993, PCF has aspired to change the face of cancer research.



PCF helped lead the 1998 March on Washington, uniting hundreds of thousands of patients, clinicians, researchers, and other advocates to support bioscience research.



PCF funding propelled the development of enzalutamide (XTANDI®), a next-generation hormone therapy that also has aided millions globally.



Our innovative funding model has helped attract nearly \$10 billion in federal funding for prostate cancer research since the 1990s.




**National Center for Advancing Translational Sciences (NCATS)**

PCF joins the Lake Tahoe Innovation Retreat, leading to the creation of NCATS, an NIH entity for translational science, signed into law.



Since 2016, PCF and the VA have partnered to improve prostate cancer care for hundreds of thousands of U.S. Veterans. Generous donors to PCF have contributed more than \$65 million to this initiative that includes 21 Centers of Excellence nationwide.




Just 15 years ago, patients with advanced prostate cancer received only androgen deprivation therapy (ADT). PCF funding was key to developing apalutamide (Erleada®), a life-extending hormone therapy approved by the FDA in 2018.

# PCF provides the best life insurance.

We identify and fund the most promising ideas from top science teams around the world and support the careers and work of brilliant young researchers.



PCF's \$14 million investment in abiraterone acetate (ZYTIGA®) catalyzed substantial additional funding for this treatment, which now extends the lives of millions worldwide.




### Women in Science

For more than a decade, PCF has advanced the trailblazing efforts of women in research labs, clinics, and leadership roles.



### PCF Home Run Challenge

500 games in every ballpark in North America.



With support from generous donors, PCF has raised \$1 billion for our lifesaving mission.



**Average survival for men has increased from 11 months in 1993 to over four years today.**

## Contents

<b>3</b>	President & CEO Letter
<b>5</b>	By the Numbers – Annual Highlights
<b>8</b>	Dr. Felix Feng: Celebrating a Legacy of Trailblazing Innovation
<b>10</b>	UroToday
<b>12</b>	Women in Science
<b>14</b>	Philanthropy Unleashes Innovation
<b>20</b>	32 Years of Impact
<b>24</b>	Annual Highlights
<b>38</b>	Young Investigator Awards
<b>42</b>	Challenge Awards
<b>50</b>	Partnerships
<b>54</b>	Community
<b>60</b>	Support Cures
<b>61</b>	Emeritus Board
<b>62</b>	Financials

### Mission Statement

The Prostate Cancer Foundation (PCF) funds the world's most promising research on the biology and treatment of prostate cancer, accelerating those discoveries into therapies and strategies designed to improve patients' quality of life and survival. PCF is committed to bringing together patients, researchers, loved ones, and clinicians as a singular community focused on reducing death and suffering from this disease.



PCF has received a 4-Star rating from Charity Navigator, the highest honor attained by less than 30 percent of US charities.



PCF meets all 20 of the Better Business Bureau's standards for charity accountability.



PCF has been designated a Top-rated Charity by Charity Watch.



## Dear Friend,

We're pleased to present the Prostate Cancer Foundation's 2025 Annual Report, which highlights our consistent efforts to harness more of society's resources – both financial and human capital – in the fight against prostate cancer.

More than three million men and their families are currently battling prostate cancer. Many millions more men will be compelled to join the fight in the coming decade. Our goal as an organization, and the focus of this year's Annual Report, is to advance innovation for patients and families all over the world.

The Annual Report summarizes PCF's accomplishments and focuses on the organization's role in accelerating global prostate cancer research. It also acknowledges PCF supporters and their significant contributions to this worthy cause.

Since our founding, PCF's work, fueled by more than \$10 billion in research investment, has helped extend and improve the lives of millions. We've seen FDA approval of 14 treatments for advanced prostate cancer, and PCF-funded discoveries are helping drive breakthroughs in dozens of other types of cancer.

We have accomplished a lot. But that's because there's a lot to do.

When brilliant, dedicated researchers and supporters come together with the right resources, innovative breakthroughs for patients and families are possible. We will continue to work tirelessly to find more effective treatments and cures for advanced forms of prostate cancer. Thank you for your continued support of PCF and your passion for making a difference!

Sincerely,

**Gina B. Carithers**  
President & CEO

### PROSTATE CANCER TODAY



## 859/day

Every day, 859 American men learn they have prostate cancer – 313,780 each year.



## 00:15

Every 15 minutes, a man dies from prostate cancer – nearly 36,000 each year, and it doesn't stop there.



## 2.9 Million

New cases of prostate cancer are expected to increase from 1.46 million to 2.9 million per year worldwide.



## 4.8%/year

Advanced prostate cancer diagnoses are rising by 4.8% per year, according to recent estimates.

**We have  
accomplished  
a lot but there  
is more work  
to be done.**



**Advanced prostate  
cancer diagnoses are  
rising by nearly 4.8%  
per year, according  
to recent estimates.**

# Annual Highlights

## **\$178 Million PCF Research Enterprise**

Managed a \$178 million active research portfolio, and raised \$56.9 million in the last year to support our urgent mission.

## **114,000 PSA TV Airings**

The "It's Your Life" PSA TV campaign is saving lives nationwide; 114,000+ airings during prime programs such as the Today Show, the Grammys, and Good Morning, America.

## **4 Million Prostate Cancer Patients**

**Individuals Living with Prostate Cancer  
in the US**

PCF designed the new PCF website to serve all men living with prostate cancer in the US and worldwide, offering a highly-tailored platform to connect patients to trusted information and resources.

## **9,169 Participants**

**PCF Webinars and Virtual Summits**

Partnered with experts to host 5 PCF Webinars and 2 virtual summits on localized and advanced prostate cancer, drawing thousands of attendees annually.

## **\$37 Million**

**Young Investigators**

Launched the next generation of top researchers by funding 30 new PCF Young Investigators, for a total of 175 active today.

## **\$98 Million**

**Team Science**

Funded high-impact, cutting-edge team science through 102 PCF Challenge Awards, including 14 new PCF Challenge Awards.

## **128,370 Veterans**

Over 128,370 U.S. Veterans can now access state-of-the art precision oncology prostate cancer care through 21+ PCF-VA Centers of Excellence.



**1 in 8  
American Men**

**will get prostate cancer  
in their lifetime.**

**1 in 6  
Black Men**

**for Black men, this risk  
increases to 1 in 6.**

# Prostate cancer is the #1 diagnosed cancer in 118 countries.

---

Since its founding, PCF spans:

**2615**

Researchers

**312**

Cancer Centers

**29**

Countries

**14**

FDA Approved  
Cancer Drugs

---

**Dr. Felix Feng**



## Celebrating a Legacy of Trailblazing Innovation

The Prostate Cancer Foundation honors the life of Dr. Felix Feng, a brilliant physician-scientist, cherished member of the PCF research family, and beloved husband and father, who passed in 2024 from cancer. A giant of oncology, Dr. Feng possessed a prescient understanding of how to harness novel technologies to personalize prostate cancer treatment, helping countless patients live longer, better lives.

Dr. Feng's journey with PCF began with a career-launching Young Investigator Award. He went on to win many more PCF awards and was a central member of two PCF-funded Dream Teams, which broke ground in identifying targetable gene variants (mutations). At the University of California, San Francisco (UCSF), his laboratory developed the first clinical-grade biomarker panels to predict treatment responses and a novel cell-free DNA biomarker to predict PARP1 inhibitor resistance. He also helped uncover how several genes drive prostate cancer progression, enabling key preclinical studies and clinical trials.

Dr. Feng founded a therapeutics firm and a start-up that uses AI to predict prostate cancer progression and benefit from hormone therapy. He skillfully collaborated with hundreds of radiation oncologists, computational scientists, molecular biologists, and others. A gifted mentor, he helped advance the careers of hundreds of young researchers. Above all, Dr. Feng cared deeply about patients, once reminding PCF Scientific Retreat attendees that "every patient involved in clinical trials is a patient like me." PCF deeply misses Dr. Feng and celebrates his legacy of leadership, perseverance, and trailblazing innovation.





### Young Investigator

Dr. Feng received 45 PCF Awards in 14 years, a singular achievement, beginning with his PCF Young Investigator Award in 2010.



### Trailblazing Innovator

Dr. Feng published over 500 peer-reviewed articles on experimental biology, clinical trials, and genomics. His leadership helped advance care for tens of thousands of patients with prostate cancer and many other types of cancer, too.



### Entrepreneur


Dr. Feng founded two groundbreaking companies, a cancer therapeutics firm and a start-up that uses AI to personalize cancer therapy.



### Gifted Mentor

Over the years, Dr. Feng mentored hundreds of PCF Young Investigators and other early-career clinician-scientists, equipping the next generation to break new ground to save and improve lives worldwide.

# UroToday—the leading global platform— 6 million visitors.



# UroToday

Since 2022, PCF has administered UroToday, the leading global platform for urology news and education. This unique and comprehensive resource reaches over 500,000 urologists and healthcare professionals worldwide, providing the latest conference news, research, and clinical practice guidelines. UroToday is also a leading peer-to-peer resource —each year, 6 million individuals visit the website. During 2025, UroToday page views rose by approximately 5%, site visits rose 25%, and social media engagement rose 22%.



**2025 VS. 2024**

**Countries Reached**  
**195/195**

**Page Views**  
**10.6M**

**Site Visitors**  
**5.9M**

**Social Media Engagement**  
**30,300**

**5%** ↑  
 Increase from 2024

**25%** ↑  
 Increase from 2024

**22%** ↑  
 Increase from Q1 2024

# Trailblazing women lead research discovery.





PCF honored world-renowned genitourinary oncologist Maha Hussain, MD, FACP, FASCO, at the first PCF Women in Science Forum in 2016. In 2025, PCF recognized Dr. Hussain for her extraordinary career in prostate cancer with the inaugural Women in Science Lifetime Achievement Award.



Panel discussions facilitate knowledge exchange, mentorship, and insight into scientific and medical leadership careers.

## Women in Science

Throughout the year, PCF celebrates the trailblazing efforts of women in research labs, clinics, and leadership roles, all with the shared mission of discovering and delivering more life-extending powerful new prostate cancer therapies and advancing screening and prevention efforts to save lives.

PCF's Scientific Retreat annually hosts a half-day Gender Equity Networking Initiative (GENI) Forum, which convenes women clinicians, scientists, and allies to advance gender equity in medical research and strengthen the pipeline of women who will lead tomorrow's breakthroughs.

A notable component of the Forum is the inclusion of girls attending high school. Attending GENI helps these students explore interests and careers in biomedicine and science, technology, engineering, and math (STEM), network, and connect with key mentors early in life for greatest impact.



# Philanthropy unleashes innovation.

With your support, PCF annually invests in the world's top scientists and teams so they can discover new cancer treatment pathways and build and sustain clinical and research capacity in the United States and worldwide. Your generous philanthropy makes each partnership, each discovery, and each new therapy possible. As a result, countless survivors are living longer, happier lives and celebrating precious milestones with loved ones around the world.



Alexander P. Cole, MD, receives his American Cancer Society (ACS) – PCF Young Investigator Award. Also pictured: ACS Senior Vice President, and Chief Diversity Officer Tawana Thomas Johnson, and PCF’s Andrea Miyahira, PhD and Howard R. Soule, PhD.



## American Cancer Society: Bridging Gaps & Identifying Disparities

Since 2023, the American Cancer Society has generously helped fund PCF’s Young Investigator Program. This investment reflects our shared commitment to extending and improving the lives of prostate cancer patients, with a particular focus on rural communities where patients may struggle to access cancer diagnostics and innovation-driven new treatments.

PCF Young Investigator Dr. Alexander P. Cole and team are bridging gaps in care by identifying disparities in accessing quality prostate cancer care in rural settings and developing a policy and implementation roadmap for equitable diffusion of advanced diagnostics and targeted interventions.



**American Cancer Society Chief Scientific Officer, William L. Dahut, MD, speaks at a PCF Scientific Retreat.**

A Global Commitment

University of California, San Francisco  
**CA**

University of Wisconsin, Madison  
**WI**

Johns Hopkins University  
**MD**

National Cancer Institute  
**NY**

Memorial Sloan Kettering Cancer Center  
**MA**

Dana Farber Cancer Institute  
**MA**

Duke University  
**NC**

Fundación Santos y de la Garza Evia, I. B. P.

**Mexico**

Sociedad Médica del Instituto Nacional de Cancerología

**Colombia**

Centro de Tratamiento e Investigación Sobre Cáncer Luis Carlos Sarmiento Angulo

Fundação Roberto Rocha Brito

**Brazil**

Instituto Oncoclínicas de Ensino, Pesquisa e Educação Médica Continuada

**Argentina**

Sociedad Italiana de Beneficencia en Buenos Aires, Hospital Italiano

Instituto Alexander Fleming



# Prostate Cancer Knows No Borders

Each year, prostate cancer is diagnosed in nearly 205,000 men in Latin America. Many have advanced or high-risk disease requiring expert management. To help fill this need, PCF and Pfizer joined forces to enhance global capacity and improve advanced prostate cancer management throughout the region.

# Advancing Best-In-Class Prostate Cancer Care in Latin America

In February 2024, Pfizer and PCF joined forces to launch a Visiting Professorship Program for Latin America. Outcomes include seven two-day medical education programs in four countries, led by clinical experts whose skills and knowledge are matched to each organization's educational needs.



## Building Local Capacity

Alicia Morgans, MD, MPH, genitourinary medical oncologist and Director of the Survivorship Program at Dana-Farber Cancer Institute, teaches at the Fundação Roberto Rocha Brito in Brazil (FRRB), affiliated with Vera Cruz Hospital.



## Innovating Solutions

Below: Fatima Karzai, MD, of the National Cancer Institute and Michael Morris, MD, of Memorial Sloan Kettering Cancer Center visit Centro de Tratamiento e Investigación Sobre Cáncer Luis Carlos Sarmiento Angulo in Bogotá, Colombia to share their expertise on innovating solutions for prostate cancer patients.



This program builds local clinical and scientific knowledge, skills, and relationships and boosts delivery of evidence-based care across the prostate cancer disease spectrum.



## Bayer Infuses Top Talent into the Next Generation of Leaders

Bayer, one of the world's largest pharmaceutical organizations, is enabling top investigators and teams to tackle some of the greatest challenges in prostate cancer today.

Bayer recently funded two PCF Young Investigators—Claire de la Calle, MD, University of Washington, and Samuel Washington III, MD, University of California, San Francisco (UCSF)—promising early-career scientists with a deep interest and commitment to prostate cancer research. Bayer's generosity infuses top talent into the next generation and drives innovation for patients worldwide.



Samuel Washington III, MD, University of California, San Francisco (UCSF) accepts the 2024 Bayer-PCF Young Investigator Award.



Dr. Antonio Tito Fojo speaks at a PCF Scientific Retreat.



**\$1.6 Million**

**Grant from Sun Pharma empowers Dr. Antonio Tito Fojo and Dr. Susan Bates to study dozens of tumors.**



## Sun Pharma's Generosity is Saving Lives

Every man with prostate cancer is unique—and so is every tumor. A transformative \$1.6 million grant from Sun Pharma empowers Dr. Antonio Tito Fojo and Dr. Susan Bates to study dozens of tumors to see how they grow and respond to treatment as part of an ongoing clinical trial opening at VA Medical Centers. This groundbreaking work will help doctors choose the right therapy for each and every patient and know when to switch treatments so men can live longer and thrive.



# Our donors helped us reach a historic milestone.

Over \$1 billion raised for our lifesaving mission. Our 30<sup>th</sup> anniversary was a banner year for patients, marked by two new FDA approvals of precision cancer treatments known as PARP Inhibitors. It was PCF team science that discovered that PARP is a critical driver of prostate cancer, and that PARP inhibitors can suppress tumor growth and progression. Your support of PCF has paved the way for these and many other groundbreaking therapies that have saved, extended, and improved the lives of millions.



1993

PCF Founded



Zometa®

2002



Taxotere®

2004



Provenge®

Xgeva®

2010



Zytiga®

2011

For over 30 years, PCF-funded research has helped drive nearly every therapeutic breakthrough in prostate cancer.



Keytruda®

2017



Xofigo®

2013



Xtandi®

2012

Dr. Charles Sawyers and Dr. Michael Jung co-discovered the anti-androgen drug Xtandi (enzalutamide), FDA-approved in 2012 for the treatment of advanced prostate cancer.



The precision medicine work of the 2012 PCF-funded International Dream Team, co-led by Arul Chinnaiyan, MD, PhD, and Charles Sawyers, MD, led to FDA approvals of new targeted treatments for prostate cancer.



2018



Erleada®



Lynparza®

Rubraca®

2020



Pluvicto®

2022



Akeega®




Talzenna®

2023

Our research fights it, your passion defeats it.


# Our work applies to multiple tumor types.



**PCF-funded advances in precision medicine propel progress in many cancers, including:**

- Bladder Cancer
- Blood Cancers
- Bone Cancers
- Brain Tumors
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Head & Neck Cancers
- Kidney Cancer
- Liver Cancer
- Lung Cancer
- Melanoma
- NUT Midline Carcinoma
- Ovarian Cancer
- Pancreatic Cancer
- Pediatric Cancers
- Stomach Cancer
- Testicular Cancer
- Thyroid Cancer


Since its peak in 1993 to 2023, the death rate from prostate cancer has dropped by about half. The decline in deaths has slowed in recent years, reflecting the rise in advanced stage cancers.



\*Data available through 2022

# We started the year inspired by your support, driven to change the world.

2024-2025 marked another period of remarkable progress, all made possible by your generosity. From January's Palm Beach Gala to October's game-changing Scientific Retreat and beyond, PCF has sustained its relentless mission to channel essential resources toward the world's best researchers, saving and extending the lives of tens of thousands of fathers, sons, and brothers.



Many Young Investigator alumni are now international prostate cancer leaders and mentors, including (pictured above, left to right) Nima Sharifi, MD, Kosj Yamoah, MD, PhD (pictured right, below), and Stacy Loeb, MD, who joined us in Palm Beach.



A recent Palm Beach Gala honored John and Daria Barry in recognition of their efforts to accelerate new life-saving treatment options for prostate cancer patients.



Thanks to our generous donors, we raised funds for 23 new Young Investigators!

JANUARY / FEBRUARY

# Annual Gala Funds Early-Career Innovative Scientists Changing the World

PCF annually kicks off the year with a Palm Beach event featuring a Pro-Am Tennis Tournament and Gala. Each year, Palm Beach raises career-launching funds for our next class of Young Investigators—3-year awards that have laid crucial groundwork for major therapeutic advances like PARP inhibitors, PSMA-targeted radioligand therapy, PSMA PET imaging, and biomarker panels to personalize prostate cancer treatment. 100% of dollars pledged at these events fund new research.



PCF's 2025 Palm Beach Gala was generously held at the elegant home of Michele Kang. This event featured world-class comedic legends Steve Martin and Martin Short for a night of humor fueling lifesaving research and awareness.

MARCH

# Passion on the Court Drives Crucial Research Funding

Tennis enthusiasts love the chance to play legendary professionals and champions while supporting our mission. PCF's March Pro-Am Tennis Event featured an evening with tennis legends who together have earned 16 grand slam titles, plus a fireside chat featuring PCF Founder and Chairman Michael Milken, a healthcare visionary who spoke on the past five decades of innovation and the future of healthcare.




**Held at the Indian Wells Tennis Garden, the tournament coincides with the BNP Paribas Open, which attracts the world's best players and is the fifth largest professional tennis tournament worldwide.**




A group shot of the players. The PCF Indian Wells event features a two-tiered round robin tournament, played over two days, which pairs amateur tennis players with a top-ranked professional.





From the journal of *European Urology* publication titled "Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA". The publication showed trends that prostate cancer incidence is rising faster and mortality is rising much higher in Black Men.




APRIL

# PCF Publishes First Ever Comprehensive Prostate Cancer Screening Guidelines for Black Men

Black men have over twice the risk of prostate cancer death compared to White men. Black men also face a higher lifetime risk of prostate cancer and tend to be affected at a younger age. Early detection saves lives, but until recently, prostate cancer screening guidelines only gave Black men a footnote.

To address this disparity, PCF convened an expert panel to create first-in-kind prostate cancer screening guidelines for Black men. Published in April 2024, the guidelines recommend Black men begin discussing PSA screening as early as age 40—and strongly consider annual screening thereafter.



MAY

# PCF Leads a Conversation on the Future of Cancer Research

Men with prostate cancer need better treatments faster. PCF's CEO and President Gina B. Carithers is making that happen—giving men more precious time with the people they love.

Recently, Carithers spoke at the Milken Institute Global Conference about breakthrough immunotherapy treatments that could save thousands of lives. Her words embody PCF's 32-year role as a funder of transformative prostate cancer research. Under her leadership, the world's best scientists are reshaping what we know about prostate cancer research and bringing hope to families everywhere.

**\$87.5 Million**

**PCF Investment in Immunotherapy since 1993.**




Pioneers of immune checkpoint therapy Dr. Jim Allison and Dr. Padmanee Sharma with PCF Leadership at PCF Scientific Retreat.



# Your Best Investment

PCF was established with more in mind than accelerating treatments and a cure for prostate cancer. From the beginning, we aspired to change the face of cancer research and to produce results that could help people suffering from a broad range of serious diseases.



**Today**

Ipilimumab is now FDA-approved in seven cancer types, and immunotherapy is a mainstay of cancer treatment alongside pillars like surgery and radiation therapy.



**2015**

**2018**

James P. Allison and Tasuku Honjo receive the Nobel Prize in Physiology or Medicine for their "discovery of cancer therapy by inhibition of negative immune regulation."



The Food and Drug Administration approves the first immune 'checkpoint inhibitor,' ipilimumab (Yervoy).

**2011**

Yervoy paves the way for other checkpoint inhibitors, including pembrolizumab. Its success treating President Jimmy Carter's metastatic melanoma explodes public awareness of these transformative therapies.

**1997**

PCF invests in pioneering work by Dr. Jim Allison for his research on a new immune therapy. Over the next decade, PCF invests \$2.1 million in this work.




**Annual Highlights**



Mike Milken joined Dodgers owner Todd Boehly and long-time PCF supporter Dr. Richard Merkin to watch the World Champion Dodgers play on Father's Day.



Mike Milken and his grandson Spencer are joined by Tony Pritzker, Cubs owner Tom Ricketts, and Tony's son Nicholas at a Cubs game.



PCF Board Member Emilio Bassini and his grandsons Levi and Max were on the field for pre-game festivities at Yankee Stadium.



**Keep Dad in the Game**  
Above: New Orioles owner David Rubenstein and Jerry Reinsdorf, who has owned the White Sox for 40 years, joined PCF Chairman Mike Milken and PCF CEO Gina Carithers in a pre-game conversation about how team owners have a responsibility to support their communities.

JUNE


# Another Year Around the Bases

PCF's Home Run Challenge has raised over \$72 million to fund breakthrough research while elevating public awareness about prostate cancer and the power of early detection. During the HRC, loyal supporters pledge donations for every Major League Baseball home run. PCF supporters have been to more than 500 games in every MLB ballpark and participated in more than 1,000 broadcasts. The HRC is the longest-running philanthropic partnership involving a professional sports league—this past June marked its 30th season!

**2025 RESULTS**

**\$1.5 Million Raised For Lifesaving Science**

**923 Home Runs**



Below: Alan Lazowski, a founder of the Milken Center for Advancing the American Dream in Washington, had a great time with his dad, Philip, and Hall of Famer Joe Torre at a Mariners-Yankees game.

JULY


# Changing the World through Life-saving Early Detection

In July, during NASCAR Weekend, PCF partnered with Pocono Raceway, Man Cave Health, and Lehigh Valley Health Network to promote awareness of men's health. Regional healthcare partners provided on-site PSA blood testing for eligible attendees. Event grand marshals, Philadelphia Eagles great Jeremiah Trotter and his son, Eagles rookie Jeremiah Jr., amplified the message that prostate cancer screening starts with a simple blood test. These efforts reached thousands of raceway attendees from all 50 states and embodied PCF's collaboration with Man Cave Health to ensure lifesaving proactive screening.




130 men screened during NASCAR weekend.

Race Car Driver Romain Grosjean teamed up with prostate cancer survivor Clayton Chitwood and spoke with PCF about taking charge of his health and the importance of getting screened for prostate cancer.



Ron Semanick and his wife, Nancy, joined PCF and Man Cave Health at a screening event in Lehigh Valley, PA. Ron has generously shared his 5-year prostate cancer journey with PCF to raise awareness and save lives.



**“Be grateful for each day, lean on your support system, and don't sweat the small stuff.”**

Ron Semanick



## Annual Highlights



Our annual gathering in the Hamptons each August has become a favorite among participants.



AUGUST

# Harnessing Passion on the Court for Research Funding

The PCF Pro-Am Tennis Tour—which includes tournaments and gala weekends in Indian Wells, CA, the Hamptons, NY, and Palm Beach, FL—are popular events scheduled during peak seasons. They provide an exciting and unique experience for amateur tennis players, a chance to foster new relationships with PCF, and opportunities to raise awareness about prostate cancer and our work to accelerate world-changing innovation. The PCF Tennis Tour culminated in August.



The tennis finals conclude at The Racquet Lounge in Southampton.



AUGUST

# Vision, Relationships Drive Innovation

PCF held its August Hamptons Gala at the Parrish Art Museum in Water Mill, NY. The event and tennis weekend annually raises millions of dollars in support of lifesaving biomedical research programs.

The summer benefit in recent years has included a Q&A with Elon Musk and comedy legend, Jerry Seinfeld. The event celebrates decades of treatment progress and millions of dollars in PCF research support, all thanks to PCF's generous donors.

By raising funds for bold innovators, the Hamptons Gala supports PCF's mission to end death and suffering from prostate cancer.



During a live auction, a generous donor coalition funded Dr. Stacy Loeb's team science proposal to study the role of a plant-based diet in preventing lethal prostate cancer.



**\$14 Million**

Thanks to our generous donors, we raised funds for 4 new Challenge Award Teams and 12 new Young Investigators!






**\$33.2 Million**  
PCF has invested \$33.2 million in diet, lifestyle, and microbiome research.



SEPTEMBER

# Dialogue at the Center for Advancing the American Dream

In September, PCF joined the opening of the Milken Center for Advancing the American Dream (MCAAD), a cultural institution focused on illuminating pathways to opportunity for all. Located in historic buildings in Washington, DC, steps from the White House, the Center focuses on four pillars: Health and Medical Research, Entrepreneurship and Innovation, Education and the Educator, and Access to Capital and Financial Empowerment. Through research, convenings, exhibitions, and public programs, the Center invites people to explore bold ideas, gain practical insight, and engage in dialogue that can bridge divides and inspire action.



In the months leading up to the opening, Dr. Andrea Miyahira, Vice President of Global Research and Innovation, joined Mike Milken, PCF Founder and Chairman, for a conversation on cancer and the microbiome.

OCTOBER

# Fostering Scientific Collaboration: PCF's Annual Scientific Retreat

The Prostate Cancer Foundation Scientific Retreat is held annually at the Omni La Costa Hotel in Carlsbad, CA. This invitation-only conference is the foremost scientific meeting in the world on the biology and treatment of prostate cancer. The diversity, novelty, and extremely high impact of the topics presented as well as that of the attendees make this a unique conference. The PCF Scientific Retreat reflects the unyielding commitment of PCF to ending death and suffering from prostate cancer. This investment by PCF fosters a collaborative culture unparalleled in any other cancer research area and has accelerated the understanding of prostate cancer biology and the treatment landscape.



**639**  
639 individuals from  
17 countries

**62**  
62 Speakers in  
Plenary Session

**158**  
Poster Presentations

**44**  
PCF Young Investigators and  
Challenge Teams Awarded

NOVEMBER / DECEMBER

## Giving Tuesday Raises over \$300,000 for Lifesaving Research

During the end of year period, Giving Tuesday ignites global generosity. Annually, PCF supporters raise hundreds of thousands of dollars, with every gift triple-matched for maximum impact. As prostate cancer cases grow, we need bold innovation in diagnosis and treatment more than ever. Your support fuels breakthroughs that will help save fathers, husbands, sons and brothers—today and for generations ahead.

**GIVING**  
**TUESDAY**

### 1200 Donors

**More than 1200 donors annually join PCF on Giving Tuesday, joining millions across the globe.**





A special in-arena presentation bringing the "Check the Box!" message to fans and the basketball community at the Naismith Basketball Hall of Fame took place, featuring leaders from the YMCA of Greater Springfield's Men of Color Health Awareness initiative.

2026 & BEYOND

# What's Ahead in 2026: Check the Box! Saving Lives Together

In 2026, the Naismith Basketball Hall of Fame and the Prostate Cancer Foundation (PCF) are joining forces to announce the launch of the "Check the Box! Saving Lives Together" initiative, a partnership dedicated to increasing awareness around the dangers of late detected prostate cancer, while encouraging individuals, particularly men of color, to prioritize regular health screenings and informed conversations with healthcare providers.

This is part of PCF's five-year long commitment to spreading prostate cancer awareness and early detection efforts through basketball, an initiative generously supported in part by the Anthony Pritzker Family Foundation. Through forums, digital storytelling, and integrated activations, "Check the Box!" aims to normalize conversations around prostate health, encourage early cancer detection, and empower men to be proactive advocates for their own well-being.



Basketball legend Nancy Lieberman, Prostate Cancer Foundation CEO Gina Carithers, Naismith Hall of Fame CEO John Doleva, and ESPN's Jay Harris joined for a live forum on awareness, education, and personal storytelling at the 2026 Panini Hoophall Classic.



A simple PSA blood test enabled Alonzo Mourning to detect prostate cancer early. Now cancer-free, he urges men to do this for themselves and their families: talk to your doctor, get screened, and check the box!

# Visionary commitment. Three generations of impact.

PCF Young Investigator Awards are force multipliers that recruit top talent, catalyze key discoveries, and equip young clinicians and researchers to help tens of thousands of cancer patients during their careers. Since 1993, PCF has supported three generations of young investigators dedicated to accelerating scientific discovery. Each of these generations have been involved in significant prostate cancer breakthroughs. Many of them now lead major medical centers. Multi-year funding and world-class mentoring are key success factors, while philanthropic investment is the ignition spark that sets off a chain reaction of hope that spans generations.



**PCF and generous donors  
have invested \$100 million in  
three generations of the PCF  
Young Investigators, helping  
nearly 500 brilliant minds  
drive innovation and progress.**

**ABOUT PCF YOUNG INVESTIGATORS**

PCF's prestigious three-year Young Investigator Awards attract and support the world's most promising young scientists as they embark on transformative careers in prostate cancer research.



“

**For scientific researchers, charitable donations are enormous engines of new opportunities—directions that wouldn't have been possible through conventional sources.”**

Leroy Hood, American Biologist

# Philanthropic Donors John and Daria Barry Play a Pivotal Role in Driving Innovation

Since 2018, John and Daria Barry have donated over \$9 million to PCF, helping transform prostate cancer care for Veterans and countless other men with this disease. With the John and Daria Barry Foundation's support, PCF is driving therapeutic innovation, precision oncology (matching the right treatment to the right patient), and national and global access to prostate cancer care. Recognizing the importance of recruiting and training top talent, the Barrys have donated \$3 million in total to fund 11 PCF Young Investigators, including a remarkable six recently.



**Altruism ripples out. The Barrys' generosity has inspired many other donations, prompting a sea change for Veterans across the country.**



## THE JOHN AND DARIA BARRY FOUNDATION IMPACT

**11**

PCF Young Investigators funded with special focus on advancing Veterans' health.

**\$3 Million**

Supported 11 PCF Young Investigators, including six recently.

**\$5 Million**

In 2018, \$5 million established two PCF-VA Centers of Excellence in New York City and Florida, two areas where large populations of Veterans needed better prostate cancer care.



# Global partnerships overcome the toughest challenges.

PCF Challenge Awards drive unprecedented collaborations. These substantial grants unite brilliant minds from top institutions worldwide, eliminating redundant efforts and tackling the toughest challenges. Sharing resources in this way compresses decades of traditional research into focused years of impact, transforming prostate cancer care and yielding key discoveries for many other types of cancer, too. As a result, countless families stay whole and celebrate precious moments together they might otherwise have missed.



## Enabling Scientists to Collaborate on the Toughest Challenges

**\$16 Million**

Recent investment by PCF and Generous Donors into Challenge Awards

**\$290 Million**

Since 2008, PCF has committed \$290 million to support team science through this program


**14 Approvals**

Number of new FDA medicines advanced through teams of scientists funded by PCF

“

**In my view, the future of medicine will be powered by AI by harnessing predictive technologies. I believe we can revolutionize how we understand and treat diseases. With AI, we can analyze vast amounts of data and work to enable advanced techniques, practices that I predict will lead to better health outcomes.”**

**Igor Tulchinsky**  
Founder, Chairman and CEO of WorldQuant



# Advancing the Future of Medicine Through Innovation


A generous gift from visionary philanthropist Igor Tulchinsky funded a cutting-edge study in the ProtecT Randomized Trial to identify biomarkers, which indicate a high risk of advanced prostate cancer, as well as susceptibility to toxicity from radiation treatment. This study uses novel methods to search for links between gene variants (mutations) and clinical outcomes. PCF-funded research is finding more and more gene variants that affect treatment efficacy, side effects, and prognosis, helping patients and doctors personalize care to extend and save lives.

FUNDER

**Igor Tulchinsky**

SCIENTIST

**Tyler Seibert, MD, PhD**



**Seibert is working to quantify the association of germline genetics with prostate cancer treatment-related severity in ways that have never been studied.**

## \$8.3 Million

Igor Tulchinsky has donated over \$8 million to PCF, helping international teams of top researchers and early-career scientists tackle the toughest questions in prostate cancer today.




# A Hair Test on the Horizon for Prostate Cancer Detection

In 2024, investigators Kenneth Pienta, MD of Johns Hopkins University in Baltimore, MD, and Emma Hammarlund, PhD of Lund University in Sweden received a PCF Challenge Award to develop a noninvasive screening test for early-stage prostate cancer that works by analyzing chemical elements in hair, a method known as “isotopic fingerprinting.”


Such work is crucial—with advanced cases rising, a reliable, noninvasive, cost-efficient, complementary screening test would help diagnose more men when their disease is still curable, saving lives and mitigating the massive economic burden of metastatic prostate cancer.

FUNDER  
**Anonymous**

SCIENTISTS  
**Kenneth Pienta, MD;  
Emma Hammarlund, PhD**



**The team is using isotopic fingerprinting of hair to detect the presence of cancer.**



# Mapping Advanced Prostate Cancer at the Cell Level

**FUNDER**

**Howard and Andrée Shore;  
Michael and Lori Milken**


**SCIENTIST**

**Joshua Lang, MD; Peter Nelson,  
MD; David Quigley, PhD**

A \$5 million PCF TACTICAL award is enabling Dr. Joshua Lang, Dr. Peter Nelson, and Dr. David Quigley to innovate new approaches for managing metastatic, lethal prostate cancer. Using novel technology to study individual prostate cancer cells, the team is creating a comprehensive 'map' of advanced prostate cancer to better understand how it works and engineer more effective ways to treat it.



The TACTICAL team named "The Felix Feng PC-SYNERGY Team" in memory of Felix Feng gathered at the 2024 PCF Scientific Retreat.



“

**The PCF Challenge Awards bring together highly experienced investigators in a dedicated, collaborative research model and provide critical funding to support innovative prostate cancer research. Research conducted with support from this program has laid the groundwork for numerous advances in prostate cancer detection, diagnosis, and treatments that have positively impacted patients' lives for over a decade.”**

**Gina B. Carithers**  
President & CEO, PCF

# Multicolor PET Imaging Aims to 'Interrogate' Prostate Cancer Disease Biology, Improve Treatment Selection

There is an urgent need for tests that noninvasively diagnose, monitor, and guide treatment choices for patients with advanced prostate cancer. To address this challenge, a generous \$1.2 million gift from The Morris and Alma Schapiro Fund is supporting a 2024 PCF Challenge Award. Jan Grimm, MD, PhD, of Memorial Sloan Kettering Cancer Center and his team are developing and testing a cutting-edge imaging test called multicolor PET, which uses novel physics principles and computer algorithms to enable standard PET machines to visualize more than one PET probe at the same time. As prostate cancer advances, it can lose expression of PSMA and gain expression of other markers. Thus, multiple PET imaging probes are needed to view the full extent of the tumor biology and if it expresses therapeutic targets.

FUNDER  
**The Morris and Alma Schapiro Fund**

SCIENTIST  
**Jan Grimm, MD, PhD**






Image from a phase 1/2, first-in-human trial by Dr. Salomon Tendler of patients with neuroendocrine prostate cancer.

# Partners make all the difference.

At the Prostate Cancer Foundation, we believe that progress is a team effort. Our partners are the driving force behind our mission, helping to raise awareness, amplify our message, and fund groundbreaking research that saves and improves lives. We are deeply grateful for their unwavering commitment and support, which drive real change in the fight against prostate cancer. Explore the incredible impact of our partners. If you're inspired to join this vital mission, connect with our team—we'd love to collaborate and make a difference together.



## Kimberly Clark Donates Over \$1 Million to Fund Groundbreaking Prostate Cancer Research

Since 2020, Kimberly Clark and its Depend® brand have donated over \$1 million to help PCF fund critical research on prostate cancer detection, treatment, and treatment selection. To support this mission, Kimberly Clark annually raises funds from September (Prostate Cancer Awareness Month) through November (Men's Health Awareness Month). High-profile ambassadors like Ernie Johnson and Emmitt Smith amplify the partnership, calling on men to prioritize their health and join the fight against prostate cancer. In the last year, Kimberly Clark raised \$300,000, funding a PCF Young Investigator.



High-profile ambassadors like Ernie Johnson (top) and Emmitt Smith (above) amplify the partnership, calling on men to prioritize their health and join the fight against prostate cancer.



## Stripping Away Stigma Around Prostate Cancer: FOX Features PCF in 'The Full Monty'

PCF was featured in 'The Real Full Monty', a national 2-hour special that aired on FOX and featured male celebrities raising men's awareness of prostate, testicular, and colorectal cancers. Hosted by Emmy-nominated actor Anthony Anderson and featuring stars like Taye Diggs, James Van Der Beek, Chris Jones, Bruno Tonioli, and Tyler Posey, the program encouraged men to seek early screening and talk openly about their health.

With honest conversations, powerful personal stories, and a bold finale choreographed by Emmy Award winner Mandy Moore, 'The Real Full Monty' program drew 1.2 million live viewers and even more watched the next day on Hulu. This meaningful and creative campaign supported both men's health and PCF's mission of saving, extending, and improving lives.



**“Through The Real Full Monty, we are leveraging the immense reach and power of broadcast to air this important call-to-action to educate viewers about cancer. If The Real Full Monty saves even one life, then having these brave men sharing their personal and poignant experiences with cancer will have been worth it.”**

Allison Wallach,  
President of Unscripted Programming  
at FOX Entertainment



## Partnerships

**\$150,000**

The Hawks donate \$150,000 to raise awareness and support the Prostate Cancer Foundation.




# Atlanta Hawks Foundation & Ressler Gertz Family Foundation Donate Over \$1 Million to Advance Medical Research Progress

The Atlanta Hawks, matched by the Tony Ressler and Jami Gertz Family Foundation, annually raise \$150,000 for crucial new research, bringing their cumulative total to \$1,077,000. The Hawks Foundation, Winship Cancer Institute of Emory University, and PCF recently sponsored a heartfelt public service announcement in which two Hawks Assistant Coaches shared their families' devastating losses and urged regular PSA screening for early, lifesaving detection.

**“I tip my cap to the Prostate Cancer Foundation for absolutely getting the word out and hitting us from all sides to be informed and educated.”**

**Mike Bray,**  
Assistant Coach, Atlanta Hawks



**“If people understand that all it takes is drawing blood, more people will go out to do it.”**

**Antonio Lang,**  
Assistant Coach, Atlanta Hawks



# Creating community to empower patients.

For nearly 4 million American men and their families fighting prostate cancer and millions more globally, PCF is a primary source for new standard-of-care and research information. We connect patients, loved ones, care providers, and scientists to critical updates, the latest developments, best practices, and news from the treatment pipeline.

**Our Work**

**Prostate Cancer & Patient Support**


**Take Action**



The new PCF website engages visitors right from the homepage through content and navigation that are tailored and relevant to their real-time interests, needs, and/or personal prostate cancer journeys.

# PCF Launches Our New Website

PCF is thrilled to have launched our new website—a platform rich with information and guidance that is easier to search and navigate. Each section is carefully tailored for patients, survivors, loved ones, caregivers, scientists, and donors. PCF's new website reflects our role as the world's leading philanthropic organization funding innovative prostate cancer research and a provider of key information and support for patients and loved ones navigating the prostate cancer journey.




# PCF's Innovative Patient Education Programs

Prostate cancer patient education is critical to empower the nearly 3 million Americans—and millions more worldwide—affected by this disease. PCF's free, evidence-based, multimedia educational resources for patients and loved ones cover all aspects of screening, diagnosis, treatment, and survivorship. They are vetted by experts and carefully tailored to each stage of the disease journey.

In the past year, PCF expanded its patient education resources thanks to key support from partners like AstraZeneca, Bayer, Blue Earth Diagnostics, Dendreon, Exelixis, Lantheus, Novartis, Pfizer, and Veracyte. These innovative programs are essential to bridge the gap between new FDA-approved therapies and patients living longer, better lives.





Hosted By  
Phillip Koo, MD

Brian Helfand,  
MD

Andrew Hahn,  
MD

Angela Jia,  
MD, PhD

Karine Tawagi,  
MD

Justin Lorentz,  
MSc

**“Excellent information,  
so well presented. Thank  
you all.”**

John A.

**“Outstanding session  
once again.”**

John R.

## New PCF Webinars Share Education and Hope

Besides funding innovative research, PCF creates world-class educational resources for patients and loved ones. Thousands of registrants attend our free live webinars, where PCF Chief Medical Officer Phillip J. Koo, MD, interviews leading experts who excel at patient communication. Discussions incorporate audience questions and videos endure on PCF.org for later viewing.

### Sample PCF Webinars:

- Immunotherapy for Prostate Cancer
- Managing Incontinence
- PSMA-targeted Therapies
- Nutrition and Exercise to Lower Heart Disease Risk
- How Oncology Nurses and Social Workers Can Help You


Visit [pcf.org/webinars](https://pcf.org/webinars) to learn more.

**“As always, PCF enlightens  
its webinar audience.  
Thanks again.”**

Roger T.

**“Thank you for your efforts  
and for this informative  
webinar!”**

Al-Hussein A.



# Prostate Cancer Patient Voices


Launched in 2023, Prostate Cancer Patient Voices is a unique, patient-centered platform designed to empower men and their loved ones with trusted knowledge, resources, and peer experiences. The website shares in-depth interviews with over 75 patients, practical information on early detection and risk factors, and guidance on all stages of the prostate cancer journey—from the first elevated PSA test to diagnosis, treatment options and selection, recovery, and survivorship.



**“[My primary care doctor] immediately suggested that I do a PSA blood test ...I didn’t know anything about prostate cancer.**

**I was 42, I still felt like I was invincible and indestructible. [After the biopsy results came back], that’s when I found out from my doctor the diagnosis was cancer...It was a scary time....Early on, I felt like all I had was my positivity. If I didn’t stay focused on my positivity, I feel like it could have gone a different way in a different direction.”**

Alex Guajardo



**“So just do some research. A lot of times they give you a couple of different options of how to approach it based on your age.**

**But I just think it does affect the couple, and you need to know how you’re going to work through it over two or three years, and then just talk about it. And you have got to be patient. And I don’t know, be open. I’ll just tell you this, be open to trying things you thought you would never do because there are options out there.”**


Mike and Lisa Boesen



**“I’ve always approached this as a journey or as an adventure, and I’m still doing that to this day...I keep a journal, I call it my gratitude journal, and I try to write in as much as possible ... I’ve always approached it that if you focus on what you’re grateful for every day, it really does change your mindset.”**

Steven Daniel

Rodolfo Llobet



## U.S. Veteran, Family Reach Milestones with PCF Research

In 2019, at age 55, Rodolfo Llobet, a U.S. Navy Veteran and father of four, was diagnosed with stage 4 prostate cancer. After 5 years, nine treatments and three clinical trials, his cancer had spread through his body. He and his wife, Kelly, wondered if he was headed for hospice.

Then the couple saw Dr. Maneesh Jain, a medical oncologist at Edward P. Evans-PCF Precision Oncology Center of Excellence at the Washington DC VA Medical Center. Dr. Jain explained how PCF-funded research had found promise in the T-DXd therapeutic antibody, normally used for breast cancer. Rodolfo and Kelly decided to try it.

The results were incredible—Rodolfo's tumors shrank, his appetite and energy improved, and his bone pain vanished. He felt so much better that he could travel again: "We took all four of our sons, rented a vehicle and drove around the Northwest for two weeks. We saw God's country out there. It's gorgeous!"

With the help of T-DXd, Rodolfo, Kelly, and their sons celebrated his 60th birthday and 25th wedding anniversary. "If it weren't for PCF stepping up and funding my doctors and their research, we wouldn't have made these milestones and done these really neat things," he said. Kelly added, "PCF's nutrition information alone is valuable. What they did for us—we can never thank them enough."


Sadly, Rodolfo passed away in June 2025. PCF extends our deepest condolences to Kelly Llobet and the entire family. As a U.S. Navy Veteran, Rodolfo served his country—and the entire prostate cancer community—with courage, generosity, and grace. We are deeply grateful for his story.



# Support Cures

Millions of men are living with prostate cancer today—and millions more will be diagnosed in the next decade. The generosity of individuals and charitable foundations drives the Prostate Cancer Foundation’s mission of accelerating treatment progress and cures.

PCF Spending Per Dollar\*



Prostate Cancer Research Mission

\*Based on 2024 Financials



**“The Prostate Cancer Foundation saved my life. Dr. Rathkopf saved my life. My wife and my family saved my life. I’m the beneficiary of all that, and I’m the luckiest person in the world.”**

Stephen Eisenmann

## We offer several ways to contribute:

### Donations

100% of your donation supports cutting-edge research led by top scientists from around the world. To make an online contribution, please visit our website at [www.pcf.org](http://www.pcf.org)

Tax ID: #95-4418411

Checks can be made out to and mailed to:

**Prostate Cancer Foundation**  
1250 Fourth Street  
Santa Monica, CA 90401  
USA

### Make a Memorial or Tribute Gift

Honor the memory of a loved one or celebrate the accomplishments of a friend or family member.

If desired, PCF can also set up a special webpage to honor your loved one and collect donations on their behalf.

### Join our Blue Ribbon Society

Make a recurring monthly contribution and join our invaluable group of loyal supporters devoted to propelling breakthrough science for men with prostate cancer.

### Matching Gifts

If your company offers an Employee Matching Gifts program, you can make your hard-earned dollars go twice as far by making a matching gift to PCF.

### Other Gift Suggestions

- Gifts of stock
- Donor Advised Fund (DAF)
- Support PCF in your estate planning
- Name PCF as a beneficiary of your IRA or life insurance policy
- Federal employees and retirees participating in the Combined Federal Campaign (CFC) can designate PCF as a beneficiary

Scan here to make a donation today!



# PCF Appoints Three New Members to Emeritus Board

PCF's Emeritus Board honors past Board members for their outstanding service to the PCF mission as they continue to enrich current and future Boards with their legacy of knowledge and insight. This past year, PCF appointed three new members to our Emeritus Board. Collectively, these individuals have contributed nearly 50 years of service to PCF's Board of Directors. We salute and applaud their commitment to **PCF's mission of ending death and suffering from prostate cancer and the millions** of dollars invested in advancing medical research that their tireless efforts have achieved. New PCF Emeritus Board Members:



**Steven A. Burd**

A visionary Chairman, President, and CEO of Safeway, Inc. (1992-2013), Mr. Burd helped secure over \$83 million for PCF, funding cutting-edge translational research and clinical trials of new treatments for lethal prostate cancer. In 2009, the Steven & Christine Burd-Safeway Distinguished Professorship at UCSF funded the work of June M. Chan, ScD, whose lifestyle research on prostate cancer has been a beacon for the field.

16

Years of Service



**David A. Ederer**

The Ederers have been instrumental in carrying out our mission for over a quarter century. Mr. Ederer, his wife Marsha, and their family have advanced PCF's presence in the Pacific Northwest, mobilizing dozens of people to donate and advocate for prostate cancer screening and awareness. A passionate supporter of PCF-funded research, Mr. Ederer has attended numerous PCF Scientific Retreats, meeting with investigators and clinicians to support collaborative, life-saving science.

25

Years of Service



**Jonathan P. Evans**

Mr. Evans and his family have been the driving force behind major research initiatives for U.S. Veterans. In all, the Evanses have donated nearly \$10 million to this work, paving the way for key discoveries in prostate cancer. The family also has championed awareness that prostate cancer runs in families.

8

Years of Service

## **Independent Auditor's Report**

To the Board of Directors  
Prostate Cancer Foundation

### **Report on the Audit of the Consolidated Financial Statements**

---

#### **Opinion**

We have audited the consolidated financial statements of Prostate Cancer Foundation, which comprise the consolidated statement of financial position as of December 31, 2024, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of Prostate Cancer Foundation as of December 31, 2024, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

#### **Basis for Opinion**

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of Prostate Cancer Foundation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### **Responsibilities of Management for the Consolidated Financial Statements**

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Prostate Cancer Foundation's ability to continue as a going concern for one year after the date that the consolidated financial statements are available to be issued.

#### **Auditor's Responsibilities for the Audit of the Consolidated Financial Statements**

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

## **Independent Auditor's Report con't**

To the Board of Directors  
Prostate Cancer Foundation

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Prostate Cancer Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Prostate Cancer Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

### **Report on Summarized Comparative Information**

We have previously audited Prostate Cancer Foundation's December 31, 2023 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated August 12, 2024. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2023, is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

*Green Hasson & Janks LLP*

GREEN HASSON & JANKS LLP

September 15, 2025

Los Angeles, California

## Consolidated Statement of Financial Position

December 31, 2024

With Summarized Totals at December 31, 2023

	Without Donor Restrictions	With Donor Restrictions	2024 Total	2023 Total
<b>ASSETS</b>				
Cash and Cash Equivalents	\$ 77,973,361	\$ -	\$ 77,973,361	\$ 50,906,155
Investments	-	-	-	701,140
Pledges Receivable (Net)	20,393,175	2,690,000	23,083,175	35,951,714
Prepaid Expenses and Other Assets	456,727	-	456,727	543,772
Right-of-Use Asset	1,555,648	-	1,555,648	548,076
Property and Equipment (Net)	338,794	-	338,794	480,202
Intangible Assets	2,390,612	-	2,390,612	2,754,862
<b>TOTAL ASSETS</b>	<b>\$ 103,108,317</b>	<b>\$ 2,690,000</b>	<b>\$ 105,798,317</b>	<b>\$ 91,885,921</b>
<b>LIABILITIES AND NET ASSETS</b>				
<b>LIABILITIES:</b>				
Accounts Payable	\$430,729	-	\$430,729	\$399,800
Accrued Liabilities	1,509,678	-	1,509,678	1,768,080
Grants Payable (Net)	54,895,441	-	54,895,441	39,330,540
Lease Liability	1,555,648	-	1,555,648	550,760
Note Payable	945,624	-	945,624	1,739,373
<b>TOTAL LIABILITIES</b>	<b>59,337,120</b>	<b>-</b>	<b>59,337,120</b>	<b>43,788,553</b>
<b>NET ASSETS:</b>				
Without Donor Restrictions	43,771,197	-	43,771,197	41,761,956
With Donor Restrictions	-	2,690,000	2,690,000	6,335,412
<b>TOTAL NET ASSETS</b>	<b>43,771,197</b>	<b>2,690,000</b>	<b>46,461,197</b>	<b>48,097,368</b>
<b>TOTAL LIABILITIES AND NET ASSETS</b>	<b>\$ 103,108,317</b>	<b>\$ 2,690,000</b>	<b>\$ 105,798,317</b>	<b>\$ 91,885,921</b>

## Consolidated Statement of Activities

Year Ended December 31, 2024

With Summarized Totals for the Year Ended December 31, 2023

	Without Donor Restrictions	With Donor Restrictions	2024 Total	2023 Total
<b>REVENUE, PUBLIC SUPPORT AND OTHER INCOME</b>				
Grants and Contributions	\$ 47,656,621	\$ 2,690,000	\$ 50,346,621	\$ 51,683,892
Sponsorships	3,960,676	-	3,960,676	3,652,000
Interest and Other Income	2,621,256	-	2,621,256	2,435,259
Net Assets Released from Donor Restrictions	6,335,412	(6,335,412)	-	-
<b>TOTAL REVENUE, PUBLIC SUPPORT AND OTHER INCOME</b>	60,573,965	(3,645,412)	56,928,553	57,771,151
<b>EXPENSES:</b>				
Program Services	50,152,588	-	50,152,588	45,458,352
Supporting Services:				
Management and General	4,741,800	-	4,741,800	4,434,981
Fundraising	3,670,336	-	3,670,336	5,178,016
<b>TOTAL EXPENSES</b>	58,564,724	-	58,564,724	55,071,349
<b>CHANGE IN NET ASSETS</b>	2,009,241	(3,645,412)	(1,636,171)	2,699,802
Net Assets - Beginning of Year	41,761,956	6,335,412	48,097,368	45,397,566
<b>NET ASSETS - END OF YEAR</b>	\$ 43,771,197	\$ 2,690,000	\$ 46,461,197	\$ 48,097,368

## Consolidated Statement of Functional Expenses

Year Ended December 31, 2024  
With Summarized Totals for the Year Ended December 31, 2023

	Program Services					Supporting Services			Total Expenses	
	Research Grants	Scientific Conferences and Programs	Public Awareness	Healthcare Provider Education	Total Program Services	Management and General	Fundraising	Total Supporting Services	2024	2023
Research Grants	\$34,415,046	\$ -	\$ -	\$ -	\$34,415,046	\$ -	\$ -	\$ -	\$34,415,046	\$29,321,704
Compensation, Benefits and Payroll Taxes	-	1,676,172	3,543,969	1,442,890	6,663,031	2,900,384	799,324	3,699,708	10,362,739	10,328,164
Outreach, Events and Meetings	-	-	2,183,876	1,853,870	4,037,746	-	849,181	849,181	4,886,927	5,910,701
Global Scientific Conferences, Conventions and Meetings	-	2,115,747	-	-	2,115,747	13,682	-	13,682	2,129,429	2,281,901
Office Expenses and Other	-	128,618	217,054	-	345,672	834,406	942,679	1,777,085	2,122,757	2,125,394
Professional Fees	-	170,695	593,985	-	764,680	741,612	360,106	1,101,718	1,866,398	1,690,573
Travel, Meals and Entertainment	-	63,110	250,281	-	313,391	81,056	642,060	723,116	1,036,507	1,256,698
Media, Public Relations and Publications	-	-	704,061	-	704,061	6,140	330	6,470	710,531	1,054,498
Occupancy	-	95,534	252,202	-	347,736	119,112	61,884	180,996	528,732	603,962
Depreciation and Amortization	-	22,152	396,576	26,750	445,478	45,408	14,772	60,180	505,658	497,754
<b>Total 2024 Functional Expenses</b>	<b>\$34,415,046</b>	<b>\$4,272,028</b>	<b>\$8,142,004</b>	<b>\$3,323,510</b>	<b>\$50,152,588</b>	<b>\$4,741,800</b>	<b>\$3,670,336</b>	<b>\$8,412,136</b>	<b>\$58,564,724</b>	<b>\$55,071,349</b>
					86%	8%	6%		100%	100%
<b>Total 2023 Functional Expenses</b>	<b>\$29,321,704</b>	<b>\$5,732,530</b>	<b>\$7,531,057</b>	<b>\$2,873,061</b>	<b>\$45,458,352</b>	<b>\$4,434,981</b>	<b>\$5,178,016</b>	<b>\$9,612,997</b>		
					83%	8%	9%			100%

## Consolidated Statement of Cash Flows

Year Ended December 31, 2024

With Summarized Totals for the Year Ended December 31, 2023

	2024	2023
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Change in Net Assets	\$ (1,636,171)	\$ 2,699,802
Adjustments to Reconcile Change in Net Assets to Net Cash Provided By Operating Activities:		
Change in Allowance for Doubtful Pledges Receivable	195,000	120,000
Change in Present Value Discount on Pledges Receivable	-	(1,182,990)
Depreciation and Amortization	505,658	497,754
(Increase) Decrease in:		
Pledges Receivable	12,673,539	4,931,121
Prepaid Expenses and Other Assets	87,045	(205,761)
Right-of-Use Asset	542,264	548,075
Increase (Decrease) in:		
Accounts Payable	30,929	(618,866)
Accrued Liabilities	(258,402)	(390,243)
Grants Payable	15,564,901	3,380,985
Lease Liability	(544,948)	(545,391)
<b>NET CASH PROVIDED BY OPERATING ACTIVITIES</b>	<b>27,159,815</b>	<b>9,234,486</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Purchase of Intangible Assets	-	(40,650)
Proceeds on Sale of Investments	701,140	6,858,888
Purchase of Investments	-	(701,140)
<b>NET CASH PROVIDED BY INVESTING ACTIVITIES</b>	<b>701,140</b>	<b>6,117,098</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Borrowing on Note Payable	-	51,873
Repayment of Note Payable	(793,749)	-
<b>NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES</b>	<b>(793,749)</b>	<b>51,873</b>
<b>NET INCREASE IN CASH AND CASH EQUIVALENTS</b>	<b>27,067,206</b>	<b>15,403,457</b>
Cash and Cash Equivalents - Beginning of Year	50,906,155	35,502,698
<b>CASH AND CASH EQUIVALENTS - END OF YEAR</b>	<b>\$ 77,973,361</b>	<b>\$ 50,906,155</b>
<b>SUPPLEMENTAL SCHEDULE OF NON-CASH OPERATING ACTIVITIES:</b>		
Right-of-Use Asset Acquired in Exchange for Lease Liability	\$ 1,549,836	\$ -
Lease Liability	\$ 1,549,836	\$ -



# Make an Impact: Support Lifesaving Research and Improve Outcomes in Patients

Visit [pcf.org/take-action](https://pcf.org/take-action)  
to learn how you can make  
a difference today.

# Board Member & Officers

**Michael Milken**

Founder and Chairman

**Kelvin A. Baggett, MD, MPH**

Managing Director  
Head of Patient Impact  
and Chair  
EMPIRIC Institute

**Emilio Bassini**

Managing Principal  
Bassini & Company

**Tricia Berns**

Board Member

**Greg Brown**

Chairman and Chief  
Executive Officer  
Motorola Solutions

**Josh Cohen**

Founder  
Partner  
City Light Capital

**Neil P. DeFeo**

Executive Partner  
Nonantum Capital Partners

**Helmy Eltoukhy, PhD**

Co-Chief Executive Officer  
and Chairman of the Board  
Guardant Health

**R. Christian B. Evensen**

Alpinista Investments

**Ralph Finerman**

Chief Financial Officer  
Treasurer and Secretary

**The Reverend Rosey Grier**

Milken Family  
Foundation

**Stuart Holden, MD**

Board Member &  
Medical Director

**Philip Kantoff, MD**

Chief Executive Officer  
Chief Medical Officer  
Co-Founder  
Convergent Therapeutics

**Freda Lewis-Hall, MD**

Board Member

**The Honorable Earle I. Mack**

Senior Partner  
Mack Company

**Shmuel Meitar**

Chairman and Founder  
Aurec Capital

**Lori Milken**

Vice President  
Prostate Cancer Foundation

**Michael Muldowney**

Chief Executive Officer  
Foxford Capital, LLC  
Managing Member  
Waterville Investment Partners

**Henry L. Nordhoff**

Chairman and Chief  
Executive Officer  
Banyan Biomarkers, Inc

**Drew Pinsky, MD**

Internist, Addictionologist  
Assistant Clinical Professor,  
Psychiatry, University of  
Southern California  
Radio and Television Host

**Neal I. Rodin**

Chairman  
International Financial  
Company, LLC  
Managing Director  
RREI, LLC

**Jason J. Safriet**

Board Member

**Richard V. Sandler**

Partner  
Maron & Sandler  
Executive Vice President  
Milken Family Foundation

**Benjamin Schenkman**

Board Member

**Keith B. Shoates**

Vice President  
Office of the CEO  
Vista Equity Partners

**Howard Shore**

Founder & Chairman  
Shore Capital Group

**Jonathan W. Simons, MD**

Chief Science Officer and  
Medical Director  
Marcus Foundation

**David A. Taglight**

Chairman  
The John Black  
Charitable Foundation

**Glenn Turner**

Executive Director and Group  
Board Member  
Ligentia Group

**Vincent "Vinnie" Viola, JD**

Chairman, Owner  
and Governor  
Florida Partners Hockey  
Club, Sunrise Sports and  
Entertainment  
The BB&T Center

**Kneeland Youngblood, MD**

Founding Partner  
Pharos Capital Group

**Jeff Zisk**

Managing Director  
Surrey Ventures

---

# Leadership Team

**Gina Carithers**

President and CEO

**Phillip J. Koo, MD**

Executive Vice President  
Chief Medical Officer

**Lori Tessel**

Chief Philanthropy Officer

**Helen Hsieh**

Executive Vice President  
Finance and Chief  
Administrative Officer

**Monica Boswell**

Senior Vice President  
Business Partnerships

**Rebecca Levine**

Senior Vice President  
Strategic Corporate  
Communications and  
Government Affairs

**Dan Otto**

Senior Vice President  
Development

**Adam Bart**

Vice President  
Development

**Shani Clayton**

Vice President  
Marketing

**Andrea K. Miyahira, PhD**

Vice President  
Global Research & Innovation

**Claire Harper**

Chief of Staff



1250 Fourth Street  
Santa Monica, CA 90401

Web [pcf.org](http://pcf.org)  
Tel **1.800.757.CURE (2873)**

 [facebook.com/PCF.org](https://facebook.com/PCF.org)  
 [@PCFnews](https://twitter.com/PCFnews)